Assertio Therapeutics Inc - Asset Resilience Ratio
Assertio Therapeutics Inc (ASRT) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Assertio Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Assertio Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ASRT current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Assertio Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Assertio Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.86 Million | 17.92% |
| Total Liquid Assets | $37.86 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Assertio Therapeutics Inc maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Assertio Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Assertio Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723 |
Drug Manufacturers - Specialty & Generic | 1.01% |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL |
Drug Manufacturers - Specialty & Generic | 5.90% |
Annual Asset Resilience Ratio for Assertio Therapeutics Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Assertio Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.92% | $53.18 Million | $266.97 Million | +2.55pp |
| 2024-12-31 | 17.37% | $49.47 Million | $284.73 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $286.42 Million | -- |
| 2020-12-31 | 0.52% | $1.58 Million | $303.27 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $932.87 Million | -- |
| 2017-12-31 | 0.12% | $1.21 Million | $1.04 Billion | -4.76pp |
| 2016-12-31 | 4.87% | $59.71 Million | $1.23 Billion | -3.10pp |
| 2015-12-31 | 7.97% | $108.68 Million | $1.36 Billion | -1.98pp |
| 2014-12-31 | 9.95% | $70.77 Million | $711.07 Million | +4.59pp |
| 2013-12-31 | 5.36% | $27.26 Million | $508.65 Million | -21.28pp |
| 2012-12-31 | 26.64% | $37.74 Million | $141.65 Million | -11.14pp |
| 2011-12-31 | 37.78% | $62.11 Million | $164.37 Million | -17.17pp |
| 2010-12-31 | 54.95% | $47.83 Million | $87.03 Million | +8.08pp |
| 2009-12-31 | 46.87% | $42.92 Million | $91.58 Million | -16.16pp |
| 2008-12-31 | 63.03% | $59.93 Million | $95.08 Million | +14.56pp |
| 2007-12-31 | 48.47% | $39.09 Million | $80.64 Million | +16.19pp |
| 2006-12-31 | 32.28% | $16.98 Million | $52.62 Million | -45.32pp |
| 2005-12-31 | 77.60% | $51.51 Million | $66.38 Million | +2.60pp |
| 2004-12-31 | 75.00% | $17.15 Million | $22.87 Million | +24.24pp |
| 2003-12-31 | 50.76% | $24.21 Million | $47.69 Million | +13.30pp |
| 2002-12-31 | 37.47% | $8.68 Million | $23.18 Million | +7.46pp |
| 2000-12-31 | 30.01% | $2.62 Million | $8.73 Million | +14.27pp |
| 1999-12-31 | 15.74% | $3.53 Million | $22.43 Million | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more